Drug Profile
Poseltinib - Hanmi Pharmaceutical
Alternative Names: HM 71224; LY 3337641Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Hanmi Pharmaceutical
- Developer Eli Lilly and Company; Hanmi Pharmaceutical
- Class Antirheumatics; Piperazines; Pyrimidines; Small molecules
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Diffuse large B cell lymphoma
- Discontinued Rheumatoid arthritis
Most Recent Events
- 08 Jun 2023 Efficacy and adverse event data from phase II trial in Diffuse large B cell lymphoma presented at the 28th Congress of the European Haematology Association (EHA-2023)
- 23 Jan 2023 Discontinued - Phase-I for Rheumatoid arthritis (In volunteers) in Netherlands, Singpaore (PO) as of January 2023 (Hanmi Pharmaceutical pipeline, January 2023; Eli lilly and company pipeline, January 2023)
- 23 Jan 2023 Discontinued - Phase-II for Rheumatoid arthritis in Argentina, Puerto Rico, Australia, Austria, USA, Japan, South Africa, South Africa, Germany, Mexico, Poland, Slovakia, South Korea, Italy, Spain (PO) as of January 2023 (Hanmi Pharmaceutical pipeline, January 2023; Eli lilly and company pipeline, January 2023)